12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Company News  |  Deals

Helsinn, Specialised Therapeutics Australia deal

Helsinn granted Specialised exclusive rights to develop and commercialize anamorelin in Australia and New Zealand to treat cachexia/anorexia in patients with non-small cell lung cancer (NSCLC). Specialised Therapeutics will be responsible for clinical and regulatory development,...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >